Ki20227

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Ki20227	Purity：98% min
CAS NO：623142-96-1	Solubility：DMSO : 7.2 mg/mL (14.98 mM)
Molecular Formula：C₂₄H₂₄N₄O₅S	Package：Package according to customer requirements
Molecular Weight：480.536	Storage：Store at -20℃

Quality control

Remarks

KI-20227 is a potent and orally active inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Ki20227 suppresses experimental autoimmune encephalomyelitis.

CSF-1R Inhibitors Related Products:

GW2580; Pazopanib; Pazopanib HCl; Linifanib; ENMD-2076; ENMD-2076 Tartrate; OSI-930; Agerafenib; PLX5622; Pexidartinib; Pexidartinib HCL; Aprepitant; Erdafitinib ; BLZ945

References

[1]. Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.

[2]. Ohno H, et al. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol. 2008 Jan;38(1):283-91.